Q-omics provides the consensus-scored C1orf54 profile across patient tissues and cancer cell-line models. C1orf54 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, C1orf54 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, C1orf54 RNA expression shows 19,070 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where C1orf54 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1orf54 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1orf54 survival associations across molecular data types. C1orf54 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1orf54 RNA expression–survival associations across cancer types. High C1orf54 expression shows unfavorable associations in UVM, ACC and LGG, but favorable associations in CHOL, SKCM and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for C1orf54 RNA expression.
This table summarizes C1orf54 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C1orf54. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1orf54 shows lower tumor expression in LUSC, BLCA and LUAD and higher tumor expression in KIRC, THCA and HNSC. The KIRC box plot shows higher C1orf54 RNA expression in tumor versus normal tissue (log2 FC = +1.261, t-test p < 0.001).
This table shows molecular features associated with C1orf54 in patient tissues and cancer cell lines. In patient samples, C1orf54 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, C1orf54 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
